检索结果-南通市图书馆

Chronic intermittent hypoxia increases beta cell mass and activates mTOR/HIF1/VEGF-A pathway in mice islet

中华医学会呼吸病学年会——2.11（第十二次全国呼吸病学学术会议）

作者： chenjuan gu,Qingyun li,{2.,shanghai ruijin Hospital,medical school of shanghai jiaotong university

The objective of this study was to determine the impact of obstructive sleep apnea hypopnea syndrome(OSAHS) on glucose metabolism and pancreatic beta cell function. A total of 179 subjects who recorded all-night polysomnography in our sleep laboratory during the period from January 2.05 to December 2.10 were enrolled in this study and were divided into

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Chronic intermittent hypoxia increases beta cell mass and ac...

Comparing the efficacy and safety of low,medium,and high dosages of selexipag for treating pulmonary hypertension:A systematic review and meta-analysis

中华医学会呼吸病学年会——2.11（第十二次全国呼吸病学学术会议）

作者： chenjuan gu,min {2.,Qingyun {2.,Ning {2. department of respiratory medicine,shanghai ruijin Hospital,medical school of shanghai jiaotong university

The objective of this study was to determine changes in pancreatic beta cell mass and islet mTOR/HIF1/VEGF-A pathway in mice subjected to chronic intermittent hypoxia,which was probably related to CIH-induced impaired glucose metabolism and beta cell dysfunction. A gas control delivery system was designed to regulate the flow of nitrogen and oxygen into a customized

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Animal Models and Experimental medicine 2024年第1期7卷 56-70页

作者： Shang Wang yi Yan Jian Zhang Ping Yuan Ci-Jun Luo Hong-ling Qiu Hui-Ting li Jian Xu Lan Wang Tian-Lan li Rong Jiang department of Cardio-Pulmonary Circulation Shanghai Pulmonary HospitalSchool of MedicineTongji UniversityShanghaiChina Heart Center and shanghai Institute of Pediatric Congenital Heart Disease Shanghai Children's Medical CenterNational Children's Medical CenterShanghai Jiaotong University School of MedicineShanghaiChina department of respiratory and Critical Care {2. The 416 Hospital of Nuclear IndustryThe Second Affiliated Hospital of Chengdu Medical CollegeChengduChina department of Hematology The Affiliated Hospital of Qingdao UniversityQingdaoChina

Background:The maintenance dosage of selexipag is categorized as low,medium or *** order to assess the efficacy and safety of different dosages of selexipag for the risk stratification of pulmonary arterial hypertension(PAH),we performed a sys-tematic review and ***:Studies assessing PAH risk stratification indices,such as the World Health Organization functional class(WHO-FC),six-minute walk distance(6MWD),N-terminal pro-B-type natriuretic peptide(NT-proBNP)level,right atrial pressure(RAP),cardiac index(CI)and mixed venous oxygen saturation(SvO2.,were ***:Thirteen studies were *** led to improvements in the 6MWD(MD:2..2. m,95%CI:10.74-37.67),NT-proBNP(SMD:-0.41,95%CI:-0.79-0.04),CI(MD:0.47 L/min/m^(2.,95%CI:0.17-0.77)and WHO-FC(OR:0.564,95%CI:0.457-0.697).Subgroup analysis demonstrated that all three dosages improved the 6MWD.A moderate dosage led to improvements in the CI(MD:0.30 L/min/m^(2.,95%CI:0.15-0.46)and WHO-FC(OR:0.589,95%CI:0.376-0.92.).Within 6 months of treatment,only the WHO-FC and CI were significantly improved(OR:0.614,95%CI:0.380-0.993;MD:0.30 L/min/m^(2.,95%CI:0.16-0.45,respectively).More than 6 months of treatment significantly improved the 6MWD,WHO-FC and NT-proBNP(MD:40.87 m,95%CI:10.97-70.77;OR:0.557,95%CI:0.440-0.705;SMD:-0.61,95%CI:-1.17-0.05,respectively).Conclusions:Low,medium,and high dosages of selexipag all exhibited good *** treatment lasted for more than 6 months,selexipag exerted obvious effects,even in the low-dosage *** finding is important for guiding individualized treatments.

关键词： individualized treatments meta-analysis prostacyclin receptor agonist risk stratification systematic review

Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children

在线全文

学校读者我要写书评

暂无评论

World Journal of Pediatrics 2024年第9期20卷 901-914页

作者： ying-Shuo Wang Yun-lian Zhou {2.an-Nan Bai Shu-Xian li Dan Xu li-Na Chen Xing Chen Xiao-Yan Dong Hong-min Fu Zhou Fu Chuang-li Hao Jian-{2.o Hong En-Mei liu Han-min liu Xiao-Xia Lu Zheng-Xiu Luo Lan-Fang Tang Man Tian Yong yin Xiao-Bo Zhang Jian-Hua Zhang Hai-lin Zhang De-Yu Zhao Shun-ying Zhao {2.o-Hong Zhu ying-Xue Zou Quan Lu Yuan-Yuan Zhang Zhi-min Chen department of Pulmonology Children’s HospitalZhejiang University School of MedicineNational Clinical Research Center for Child HealthHangzhou 310052China department of Child Health Care Children’s HospitalZhejiang University School of MedicineNational Clinical Research Center for Child HealthHangzhou 310052China department of Pediatric Pulmonology and Immunology West China Second University HospitalSichuan UniversityChengdu 610041China department of Pediatrics Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinan 250021China department of Pulmonology Shanghai Children’s HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200062China department of Pulmonary and Critical Care medicine Kunming Children’s HospitalKunming 650034China department of respiratory {2. Children’s Hospital of Chongqing Medical UniversityChongqing 400014China department of Pulmonology Children’s Hospital of Soochow UniversitySuzhou 215003China department of Pediatrics Shanghai General Hospital Affiliated to Shanghai Jiaotong University School of MedicineShanghai 200080China department of respiratory {2. Wuhan Children’s HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430015China department of respiratory {2. Children’s Hospital of Nanjing Medical UniversityNanjing 210008China department of respiratory {2. Shanghai Children’s Medical CenterShanghai Jiao Tong University School of MedicineShanghai 200127China department of respiratory {2. Children’s Hospital of Fudan UniversityShanghai 201102China department of Pediatric Pulmonology Xinhua HospitalShanghai Jiaotong University School of MedicineShanghai 201102China department of Pediatric respiratory {2. The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical UniversityWenzhou 325027China National Clinical Research Center for respiratory Diseases Beijing Children’s HospitalCapital Medical UniversityBeijing 100045China Departmen

Background Mycoplasma pneumoniae(***)is a significant contributor to community-acquired pneumonia among *** 1968,when a strain of *** resistant to macrolide antibiotics was initially reported in Japan,macrolide-resistant ***(MRMP)has been documented in many countries worldwide,with var{2.ng incidence *** infections lead to a poor response to macrolide antibiotics,frequently resulting in prolonged fever,extended antibiotic treatment,increased hospitalization,intensive care unit admissions,and a significantly higher proportion of patients receiving glucocorticoids or second-line *** 2.00,the global incidence of MRMP has gradually increased,especially in East Asia,which has posed a serious challenge to the treatment of *** infections in children and attracted widespread attention from ***,there is still no global consensus on the diagnosis and treatment of MRMP in *** We organized 2. Chinese experts majoring in pediatric pulmonology and epidemiology to write the world’s first consensus on the diagnosis and treatment of pediatric MRMP pneumonia,based on evidence *** evidence searches and reviews were conducted using electronic databases,including PubMed,Embase,Web of Science,CNKI,Medline,and the Cochrane *** used variations in terms for“macrolide-resistant”,“Mycoplasma pneumoniae”,“MP”,“***”,“pneumonia”,“MRMP”,“lower respiratory tract infection”,“Mycoplasma pneumoniae infection”,“children”,and“pediatric”.Results Epidemiology,pathogenesis,clinical manifestations,early identification,laboratory examination,principles of antibiotic use,application of glucocorticoids and intravenous immunoglobulin,and precautions for bronchoscopy are *** and rapid identification of gene mutations associated with MRMP is now available by polymerase chain reaction and fluorescent probe techniques in respiratory *** the resistance rate to mac

关键词： Child Macrolide-resistant Mycoplasma pneumoniae Recommendation Diagnosis Treatment

Treatment of pediatric mild persistent asthma with low-dose budesonide inhalation suspension *** in China

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Pediatrics 2021年第6期17卷 619-625页

作者： Zhi-min Chen De-Yu Zhao li {2. Jian-guo Hong department of respiratory Diseases Children's HospitalZhejiang University School of MedicineHangzhou 310006China department of respiratory Diseases Children's Hospital of Nanjing Medical UniversityNanjing 210029China department of Allergy Beijing Children's HospitalCapital Medical UniversityNational Children's Hospital CenterBeijing 100045China department of Pediatrics Shanghai General HospitalShanghai Jiaotong UniversityNo.100Haining RoadHongkou DistrictShanghai 200080China

Background There are limited studies comparing budesonide inhalation suspension(BIS)with montelukast in real-world settings where treatment adherence and persistency may be *** real-world study aims to investigate the control effectiveness of montelukast or BIS as a monotherapy in Chinese children with mild *** Data were derived from a retrospective questionnaire-based analysis of 2.14-year-old children with mild persistent asthma,who received either 500 pg of BIS(n=153)or 4-5 mg of montelukast(n=2.0)once *** indicators of asthma control,the Asthma Control Test(ACT)/Childhood ACT(C-ACT)score,and the asthma-related medical costs were *** differences between the two groups were compared using an unpaired-t-test(normally distributed).Mann-Whitney U test(non-normally distributed)or chi-squared test(categorical variables).Results Medication compliance in the past 3-month period was better in the montelukast group than in the BIS group(P=0.042..The montelukast group exhibited better asthma control in the past 4-week period,including lower percentages of asthmatic children with symptoms more than twice a week(P=0.02.),had night waking or night coughing(P=0.02.),or required reliever medication more than twice a week(P2.months(Pmedical expenditures attributable to asthma in the past 12.months were observed in the BIS group *** group(Pliever medication and more medical expenditures attributable to asthma were needed for BIS *** in real-world settings,where factors such as compliance were also taken into account.

关键词： Allergic rhinitis Asthma Budesonide Child Montelukast

Access block and prolonged length of stay in the emergency department are associated with a higher patient mortality rate

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Emergency medicine 2022年第1期13卷 59-64页

作者： Ting Cheng Qian Peng Ya-qing Jin Hong-jie Yu Pei-song Zhong Wei-min gu Xiao-shan Wang {2.-ming Lu li Luo department of respiratory and Critical Care {2. Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai 200025China Institute of respiratory Diseases Shanghai Jiaotong University School of MedicineShanghai 200025China shanghai Key Laboratory of Emergency Prevention Diagnosis and Treatment of Respiratory Infectious DiseasesShanghai 200025China school of Public Health Fudan UniversityShanghai 200032China Jiading District Center for Disease Control and Prevention Shanghai 201800China department of Statistical Information Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai 201801China department of Emergency Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai 200025China Key Laboratory of Public Health Safety of the ministry of Education and Key Laboratory of Health Technology Assessment of the ministry of Health Fudan UniversityShanghai 200032China

Access block,known as exit block or boarding,is defined as a situation in which patients who are admitted or planned for admission remain in the emergency department(ED)as they are unable to be transferred to an inpatient unit within a reasonable time frame(no longer than 8 hours).[1,2.Access block often occurs due to insufficient hospital capacity and is a major issue in emergency medicine.[3]

关键词： Access admitted transferred

ROLE OF TOLL-liKE RECEPTOR 4 IN AIRWAY INFLAMMATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES

在线全文

学校读者我要写书评

暂无评论

Journal of shanghai Second medical {2.(Foreign Language Edition) 2008年第1期20卷 38-41页

作者：周敏戎霞君万欢英黄绍光李彪李敏 department of respiratory Disease Ruijin Hospital School of Medicine Shanghai Jiaotong University

Objective To confirm if pulmonary epithelial cells express Toll-like receptor 4 （TLR4） and investigate the role of TLR4 in airway inflammation of chronic obstructive pulmonary diseases （COPD）. Methods The expressions of TLR4, IL-8 mRNA and NF-KB activation stimulated by differen factors E lipopolysacharides （LPS）, interleukin-lβ, cigarette smoking extract （CSE）] in pulmonary epithelial cells were investigated. Results LPS, CSE and IL-lβ induced the production of IL-8 and activation of NF-KB. The levels of 1L-8 mRNA and NF-KB protein in E1A ＋ cell were markedly higher than E1A- cell and A549 cell （ P 〈0. 05）. The TLR4 mRNA of all the cells increased along with the increase of LPS＇ stimulated time. There was significant difference among different LPS＇ doses （ 12.h： P = O. 039 ; 2. h ： P = O. 013 ）. The TLR4 mRNA of E1A ＋ cell was higher than the other two groups （ P 〈0. 05）. IL-lβ induced all the cells expressing TLR4 mRNA. CSE had no effect on the expression of TLR4 mRNA. Conclusion Pulmonary epithelial cells express TLR4. LPS and IL-lβ up-regulate IL-8 mediated via the activation of NF-KB induced by TLR4. But CSE up-regulates IL-8 mediated via the activation of NF-KB, which has no relation to TLR4 and may have another signal transduction pathway.

关键词： Toll-like receptor 4 pulmonary epithelial cells chronic airway inflammation

Genome-wide analysis identify novel germline genetic variations in ADCY1 influencing platinum-based chemotherapy response in nonsmall cell lung cancer

在线全文

学校读者我要写书评

暂无评论

Acta Pharmaceutica Sinica B 2022年第3期12卷 1514-1522页

作者： Chenxue Mao Juan Chen Ting Zou Yuankang Zhou Junyan liu Xi li {2.ping li min li Pinhua Pan Wei Zhuo Yang Gao Shuo Hu Desheng Xiao lin Wu Zhan Wang Heng Xu Wen Yang yingjie Xu Haihua Xiao Kazuhiko Hanada Wei Zhang Honghao Zhou Jiye yin Zhaoqian liu departments of Clinical Pharmacology and Pharmacy Hunan Key Laboratory of Pharmacogeneticsand National Clinical Research Center for Geriatric DisordersXiangya HospitalCentral South UniversityChangsha 410008China Institute of Clinical Pharmacology Engineering Research Center of Applied Technology of PharmacogenomicsMinistry of EducationCentral South UniversityChangsha 410078China department of respiratory Xiangya HospitalCentral South UniversityChangsha 410008China department of Thoracic Surgery Xiangya HospitalCentral South UniversityChangsha 410008China department of Nuclear medicine Xiangya HospitalCentral South UniversityChangsha 410008China department of Pathology Xiangya HospitalCentral South UniversityChangsha 410014China department of Thoracic medicine Hunan Cancer HospitalChangsha 410014China department of medical Oncology Lung Cancer and Gastrointestinal UnitHunan Cancer HospitalChengdu 610000China State Key Laboratory of Biotherapy and Cancer Center West China HospitalSichuan University and Collaborative Innovation Center of BiotherapyChengdu 610000China department of Molecular and Cellular Biochemistry School of MedicineShanghai Jiaotong UniversityShanghai 200025China Beijing National Laboratory for Molecular Sciences State Key Laboratory of Polymer Physics and ChemistryInstitute of ChemistryChinese Academy of SciencesBeijing 100190China department of Pharmacometrics and Pharmacokinetics Meiji Pharmaceutical university Tokyo 204-8588Japan

To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma(NSCLC),we performed a two-cohort of genome-wide association studies(GWAS),including 34 for WES-based and 433 for microarray-based analyses,as well as two independent validation *** integrating the results of two studies,the genetic variations related to the platinum-based chemotherapy response were further determined by fine-mapping in 838 samples,and their potential functional impact were investigated by eQTL analysis and in vitro cell *** found that a total of 68 variations were significant at P2.2.independent samples.A total of541 SNPs were significant at P2.discovery stage,of which 8 SNPs were verified in 347 independent *** the validated SNPs in two GWAS,ADCY1 gene was verified in both independent *** results of fine-mapping showed that the G allele carriers of ADCY1rs2.80496 and C allele carriers of rs189178649 were more likely to be resistant to platinum-based *** conclusion,our study found that rs2.80496 and rs189178649 in ADCY1 gene were associated the sensitivity of platinum-based chemotherapy in NSCLC patients.

关键词： Pharmacogenomics NSCLC Platinum GWAS WES ADCY1 Precious medicine SNPs

蜡样芽孢杆菌引起白血病患儿化脓性脑膜炎病例报道并文献复习

在线全文

学校读者我要写书评

暂无评论

医药论坛杂志 2024年第3期45卷 229-233页

作者：裴晓杭朱尊民雷平冲王同保楚亚菲张丽娜王志华河南省人民医院郑州大学人民医院血液内科郑州450003 河南省人民医院郑州大学人民医院检验科郑州450003 河南省人民医院肾内科河南省肾脏病免疫重点实验室郑州大学人民医院郑州450003 上海交通大学医学院附属第九人民医院呼吸与危重症医学科上海200011

目的探讨蜡样芽孢杆菌引起白血病患儿化脓性脑膜炎的病例特点,提高对蜡样芽孢杆菌引起白血病患儿化脓性脑膜炎的认识。方法回顾性分析河南省人民医院2.2.年8月收治的1例蜡样芽孢杆菌化脓性脑膜炎的白血病患儿临床资料,并检索及复习相... 详细信息

目的探讨蜡样芽孢杆菌引起白血病患儿化脓性脑膜炎的病例特点,提高对蜡样芽孢杆菌引起白血病患儿化脓性脑膜炎的认识。方法回顾性分析河南省人民医院2.2.年8月收治的1例蜡样芽孢杆菌化脓性脑膜炎的白血病患儿临床资料,并检索及复习相关文献。结果患儿,男,11岁,确诊急性淋巴细胞白血病11月余,化疗后粒细胞缺乏期由不洁饮食引起低热、恶心和腹痛,经验性抗感染治疗效果差,很快出现意识障碍、呼吸困难,头颅CT提示脑水肿,腰穿脑脊液呈黄色、白细胞及蛋白明显升高,血培养提示蜡样芽孢杆菌感染。结合患儿症状及实验室检查,考虑蜡样芽孢杆菌引起的化脓性脑膜炎,调整抗感染治疗方案为“替考拉宁+伏立康唑+美罗培南”,同时应用气管插管呼吸机辅助呼吸,患儿病情无明显好转,家属因经济问题自动出院。结论白血病患儿粒细胞缺乏是感染的高危因素,如感染蜡样芽孢杆菌进展较快,威胁患儿生命,临床医生应提高警惕。

关键词：蜡样芽孢杆菌白血病化脓性脑膜炎